» Articles » PMID: 21893543

Evaluation of Vaccines Against Enteric Infections: a Clinical and Public Health Research Agenda for Developing Countries

Overview
Specialty Biology
Date 2011 Sep 7
PMID 21893543
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Enteric infections are a major cause of morbidity and mortality in developing countries. To date, vaccines have played a limited role in public health efforts to control enteric infections. Licensed vaccines exist for cholera and typhoid, but these vaccines are used primarily for travellers; and there are two internationally licensed vaccines for rotavirus, but they are mainly used in affluent countries. The reasons that enteric vaccines are little used in developing countries are multiple, and certainly include financial and political constraints. Also important is the need for more cogent evidence on the performance of enteric vaccines in developing country populations. A partial inventory of research questions would include: (i) does the vaccine perform well in the most relevant settings? (ii) does the vaccine perform well in all epidemiologically relevant age groups? (iii) is there adequate evidence of vaccine safety once the vaccines have been deployed in developing countries? (iv) how effective is the vaccine when given in conjunction with non-vaccine cointerventions? (v) what is the level of vaccine protection against all relevant outcomes? and (vi) what is the expected population level of vaccine protection, including both direct and herd vaccine protective effects? Provision of evidence addressing these questions will help expand the use of enteric vaccines in developing countries.

Citing Articles

Research prioritisation in preparedness for and response to outbreaks of high-consequence pathogens: a scoping review.

Antonio E, Pulik N, Ibrahim S, Adenipekun A, Levanita S, Foster I BMC Med. 2025; 23(1):147.

PMID: 40059172 PMC: 11892158. DOI: 10.1186/s12916-025-03973-8.


Total coliforms as an indicator of human enterovirus presence in surface water across Tianjin city, China.

Miao J, Guo X, Liu W, Yang D, Shen Z, Qiu Z BMC Infect Dis. 2018; 18(1):542.

PMID: 30382895 PMC: 6211496. DOI: 10.1186/s12879-018-3438-5.


A universal polysaccharide conjugated vaccine against O111 E. coli.

Andrade G, New R, SantAnna O, Williams N, Alves R, Pimenta D Hum Vaccin Immunother. 2014; 10(10):2864-74.

PMID: 25483465 PMC: 5443078. DOI: 10.4161/21645515.2014.972145.


Economics and financing of vaccines for diarrheal diseases.

Bartsch S, Lee B Hum Vaccin Immunother. 2014; 10(6):1568-81.

PMID: 24755623 PMC: 5396249. DOI: 10.4161/hv.28885.


Vaccines for the prevention of diarrhea due to cholera, shigella, ETEC and rotavirus.

Das J, Tripathi A, Ali A, Hassan A, Dojosoeandy C, Bhutta Z BMC Public Health. 2014; 13 Suppl 3:S11.

PMID: 24564510 PMC: 3847224. DOI: 10.1186/1471-2458-13-S3-S11.


References
1.
Jeuland M, Cook J, Poulos C, Clemens J, Whittington D . Cost-effectiveness of new-generation oral cholera vaccines: a multisite analysis. Value Health. 2009; 12(6):899-908. DOI: 10.1111/j.1524-4733.2009.00562.x. View

2.
Serazin A, Shackelton L, Wilson C, Bhan M . Improving the performance of enteric vaccines in the developing world. Nat Immunol. 2010; 11(9):769-73. DOI: 10.1038/ni0910-769. View

3.
Jiang V, Jiang B, Tate J, Parashar U, Patel M . Performance of rotavirus vaccines in developed and developing countries. Hum Vaccin. 2010; 6(7):532-42. PMC: 3322519. DOI: 10.4161/hv.6.7.11278. View

4.
Colwell R, Huq A, Islam M, Aziz K, Yunus M, Khan N . Reduction of cholera in Bangladeshi villages by simple filtration. Proc Natl Acad Sci U S A. 2003; 100(3):1051-5. PMC: 298724. DOI: 10.1073/pnas.0237386100. View

5.
Ali M, Canh D, Clemens J, Park J, von Seidlein L, Thiem V . The vaccine data link in Nha Trang, Vietnam: a progress report on the implementation of a database to detect adverse events related to vaccinations. Vaccine. 2003; 21(15):1681-6. DOI: 10.1016/s0264-410x(02)00633-3. View